Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25244075 | 0.86 | GAA (0.32) | GAA | |
| SCHEMBL31355659 | 0.83 | GAA (0.30) | GAA | |
| SCHEMBL25415186 | 0.80 | — | — | |
| SCHEMBL26623643 | 0.77 | — | — | |
| SCHEMBL21379233 | 0.77 | — | — | |
| SCHEMBL29592633 | 0.77 | — | — | |
| SCHEMBL24712079 | 0.75 | — | — | |
| SCHEMBL25205912 | 0.75 | TNKS (0.33) | — | |
| SCHEMBL27137721 | 0.75 | — | — | |
| SCHEMBL25336522 | 0.74 | PIN1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731262-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | Astellas Pharma Inc. (JP) | 2026-04-29 | — | — | EP | disclosed |
| US-20260049072-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC (JP) | 2026-02-19 | — | — | US | disclosed |
| US-20260042771-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12V MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC. (JP) | 2026-02-12 | — | — | US | disclosed |
| US-20250388569-A1 | HETEROCYCLIC COMPOUND FOR INHIBITING AND/OR INDUCING DEGRADATION OF KRAS PROTEIN | ASTELLAS PHARMA INC. (JP) | 2025-12-25 | — | — | US | disclosed |
| US-20250206751-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC. (JP) | 2025-06-26 | — | — | US | disclosed |
| EP-4570794-A1 | HETEROCYCLIC COMPOUND FOR INHIBITING AND/OR INDUCING DEGRADATION OF KRAS PROTEIN | Astellas Pharma, Inc. (JP) | 2025-06-18 | — | — | EP | disclosed |
| EP-4570795-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12V MUTANT KRAS PROTEIN | Astellas Pharma, Inc. (JP) | 2025-06-18 | — | — | EP | disclosed |
| EP-4567033-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF MUTANT KRAS PROTEIN | Astellas Pharma Inc. (JP) | 2025-06-11 | — | — | EP | disclosed |
| EP-4559906-A1 | HETEROCYCLIC COMPOUND THAT ACTS ON G12D MUTANT KRAS PROTEIN | Astellas Pharma Inc. (JP) | 2025-05-28 | — | — | EP | disclosed |
| US-20250145631-A1 | HETEROCYCLIC COMPOUND ACTING ON G12D MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC. (JP) | 2025-05-08 | — | — | US | disclosed |
| EP-4491624-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | Astellas Pharma Inc. (JP) | 2025-01-15 | — | — | EP | disclosed |
| WO-2024261257-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024261256-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A pan-KRAS DEGRADER | ASTELLAS PHARMA INC. (JP) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024034123-A1 | PHARMACEUTICAL COMPOSITION CONTAINING HETEROCYCLIC COMPOUND | アステラス製薬株式会社 | 2024-02-15 | — | — | WO | disclosed |
| WO-2024034593-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12V MUTANT KRAS PROTEIN | アステラス製薬株式会社 | 2024-02-15 | — | — | WO | disclosed |
| WO-2024034657-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HETEROCYCLIC COMPOUND | アステラス製薬株式会社 | 2024-02-15 | — | — | WO | disclosed |
| WO-2024034591-A1 | HETEROCYCLIC COMPOUND FOR INHIBITING AND/OR INDUCING DEGRADATION OF KRAS PROTEIN | アステラス製薬株式会社 | 2024-02-15 | — | — | WO | disclosed |
| WO-2024029613-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF MUTANT KRAS PROTEIN | アステラス製薬株式会社 | 2024-02-08 | — | — | WO | disclosed |
| WO-2024019103-A1 | HETEROCYCLIC COMPOUND THAT ACTS ON G12D MUTANT KRAS PROTEIN | アステラス製薬株式会社 | 2024-01-25 | — | — | WO | disclosed |
| WO-2023171781-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | アステラス製薬株式会社 | 2023-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042771-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12V MUTANT KRAS PROTEIN | KRAS, NRAS, HRAS | GAA 3939/4885 |
| US-20250206751-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | KRAS, NRAS, HRAS | GAA 1576/4885 |
| US-20250145631-A1 | HETEROCYCLIC COMPOUND ACTING ON G12D MUTANT KRAS PROTEIN | KRAS, NRAS, HRAS | GAA 1801/4885 |
| US-20250388569-A1 | HETEROCYCLIC COMPOUND FOR INHIBITING AND/OR INDUCING DEGRADATION OF KRAS PROTEIN | KRAS, NRAS, HRAS | GAA 3542/4885 |
| US-20260049072-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF MUTANT KRAS PROTEIN | KRAS, NRAS, HRAS | GAA 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.